Stockreport

SAB Biotherapeutics Provides Company Update for Q1 2022 Financial Results

SAB Biotherapeutics, Inc.  (SABS) 
PDF Full data from Phase 2a trial that evaluated SAB-176 for treatment of seasonal influenza expected third quarter 2022 – first clinical data set from novel platform Phase [Read more]